These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31164454)

  • 1. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
    Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
    Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
    Yu KH; Ozer M; Cockrum P; Surinach A; Wang S; Chu BC
    Cancer Med; 2021 Dec; 10(24):8934-8943. PubMed ID: 34811961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center.
    Ellithi M; Abdallah M; Fischer M; Ailts I; Fanta J; Waligoske K; Bell M; Nelson ME; Bleeker J
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):479-486. PubMed ID: 35400291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
    Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
    Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
    Colloca GA; Venturino A; Guarneri D
    Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
    Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma.
    Kim HW; Lee JC; Paik KH; Lee YS; Hwang JH; Kim J
    Medicine (Baltimore); 2015 Jun; 94(25):e1012. PubMed ID: 26107667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma.
    Lu Y; Zhou Y; Cao Y; Shi Z; Meng Q
    Med Sci Monit; 2019 May; 25():3683-3691. PubMed ID: 31102397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma.
    Varzaru B; Iacob RA; Croitoru AE; Iacob SM; Radu CE; Dumitrescu SM; Gheorghe C
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
    Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
    Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.